Shares of Agomab Therapeutics fell about 8% in their Nasdaq debut on Friday, valuing the Belgium-based company at $716.4 million. ...

Key Takeaways Kodiak Sciences stock surges as late-stage programs for DR, wet AMD and macular edema drive momentum.KOD's tarcocimab, KSI-501 and KSI-101 are in pivotal studies with multiple top-line readouts through 2027.Kodiak Sciences bolstered its balance sheet via an 8.0M-share equity offering, extending its cash runway.Kodiak Sciences’ (KOD) shares have surged 24% over the past three months, driven by strong momentum around its late-stage pipeline and improving financial position, which have boosted in ...

PHILADELPHIA, Feb. 6, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023 through December 26, 2025 (the "Class Period"). Investor Deadline: Investors who purchased Ultragenyx common stock during the Class Period may, no later than April 6, 2026, seek to ...

Opko Health Inc. (NASDAQ:OPK) is one of the best stocks under $3 to invest in. On February 4, Opko Health Inc. (NASDAQ:OPK) announced it expanded its partnership with Entera Bio Ltd., a company developing oral peptide and protein replacement therapies, to advance the first oral long-acting PTH analog (LA-PTH) treatment for patients with hypoparathyroidism, in the form of a once-daily tablet. The two companies have also jointly decided to accelerate development on this medication and expect to file an Inves ...

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the best stocks under $3 to invest in. On January 9, Iovance Biotherapeutics Inc. (NASDAQ:IOVA) announced that it expects to achieve its previously disclosed full-year 2025 revenue guidance range of $250 to $300 million in the first full calendar year of Amtagvi sales. The company also expects Amtagvi, Iovance’s treatment regimen for advanced melanoma, will have up to $1 billion in peak sales potential. Iovance Biotherapeutics (IOVA) Gives Update on Rev ...

February 6, 2026 Q4 AND FULL YEAR 2025 FINANCIAL RESULTS AND BUSINESS UPDATE FORWARD-LOOKING STATEMENTS This presentation and discussions during this conference call contain forward-looking statements, relating to: our strategy and plans; potential of, and expectations for, our commercial business and pipeline programs; capital allocation and investment strategy; clinical development programs, clinical trials, and data readouts and presentations; regulatory discussions, submissions, filings, and approvals; ...

INCHEON, South Korea, Feb. 6, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider, confirming alignment with globally recognized standards. The validation confirms that Samsung Biologics' PCF calculation methodology complies with global standards, including ISO 14067 and PAS 2050. This ...

LOS ANGELES--(BUSINESS WIRE)--Mereo BioPharma Group plc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MREO. ...

NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy), to be presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held in San Diego, California. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are pleased to share data at this year’s ACTRIMS annual meetin ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 P<0.0001). Brepocitinib demonstrated rapid, deep and sustained improvements across all other efficacy endpoints measured with consistent safety profilePriovant plans to progress CS to a pivotal program with a Phase 3 study starting in calendar year 2026 following engagement with the FDA, representing the third indicat ...